Cygnus technologies, Inc.是美國一家專門從事生物工程和製藥過程中殘留物檢測的一係列產品。生物製品生產過程中存在許多影響產品質量的殘留物，諸如特殊重組表達係統中宿主細胞蛋白（ Host Cell protein, HCP ）的殘留以及生物製品加工過程中培養物殘留的汙染物。
* 檢測宿主細胞蛋白殘留和生物製品生產過程汙染物(Elisa 8008app幸福宝软件站盒）；
* 檢測並鑒定常用重組表達係統中的宿主細胞蛋白（WesternBlotting 站长统计幸福宝app）
美國一家專門從事生物工程和製藥過程中殘留物檢測的一係列產品。生物製品生產過程中存在許多影響產品質量的殘留物，諸如特殊重組表達係統中宿主細胞蛋白（ Host Cell protein, HCP ）的殘留以及生物製品加工過程中培養物殘留的汙染物。
Cygnus Technologies is the leading provider of *****s and services for the detection and characterization of impurities, such as host cell proteins, in biopharmaceuticals. Building on innovative, proprietary technology, the company develops highly specialized analytical products that meet the unique needs of the pharmaceutical, vaccine, gene therapy, and biotechnology industries.
Impurity analysis is an important step in biotherapeutic regulatory approval and quality control processes. With kits, immuno***** reagents, orthogonal analysis services, and expert advice, Cygnus Technologies helps biopharmaceutical companies accelerate the movement of new therapeutics through the development and approval stages to market.
Cygnus Technologies also offers outsourcing capabilities, using highly specialized technologies to develop custom, target-specific antibodies and *****s. A privately held company, Cygnus Technologies was acquired by Maravai LifeSciences in 2016.
20-Year History of Quality and Innovation
Origin Cygnus Kits circa 1997
Cygnus Technologies is founded with the publication of a review article demonstrating a novel approach to host cell protein analysis
First generic ELISA kit for analysis of CHO and E. coli host cell proteins from Cygnus Technologies. Kits for a wide range of expression systems were developed in the coming years.
Cygnus Technologies began offering orthogonal services for the identification of individual host cell proteins. These services include 2D western blot and 2D HPLC
Cygnus Technologies introduced kits for host cell DNA extraction and detection
D100T -- DNA Extraction Kit in Tubes
Antibody Affinity Extraction
Introduced a new method – antibody affinity extraction (AAE) – to replace 2D western blot *****s.
Cygnus Technologies demonstrated efficacy of integrating orthogonal data from mass spectrometry analysis and AAE
Maravai LifeSciences Logo
Strategic investment by Maravai LifeSciences
HCP ELISA kits introduced for the detection of HeLa and MDCK
F810 HeLa ELISA Kit
Maravai LifeSciences Logo
Cygnus Technologies attained ISO 9001:2015 Certification
Launched the EndonucleaseGTP® ELISA Kit used in quality control during viral vector and vaccine manufacturing
F960 EndonucleaseGTP ELISA Kit
Maravai LifeSciences acquired MockV Solutions to further strengthen its position in bioprocess impurity analytics with products for viral clearance testing. MockV Solutions has been integrated into Cygnus operations.
Number of Employees:30+
Facilities:Headquarters, R&D and manufacturing in Southport, North Carolina, USA.
Key Technology:Proprietary immuno*****s and orthogonal analytical methods for detecting and characterizing impurities in biotherapeutics.
Management:Ken Hoffman, Founder
Ken Hoffman founded Cygnus Technologies in 1997 to provide analytical solutions to the rapidly growing biopharmaceutical industry and is a thought leader in the field of biotherapeutic impurity analysis. Prior to starting Cygnus, Ken worked in the clinical diagnostics field for a number of companies, including bioMerieux, developing automated systems and extensive menus of *****s for infectious disease, metabolic disease, drugs and hormones. Ken holds multiple degrees, including a M.S. in Radiation biology/Immunology from University of Iowa and a Certificate in Biomedical Research Management from the Harvard School of Public Health.
Christine Dolan, Chief Operating Officer
Christine was appointed COO for Cygnus Technologies in October 2017. She is accountable for all operations including designing / implementing business processes and organizational structures / strategies to ensure continued longevity and growth. Prior to joining Cygnus Technologies, she was the SVP of Product Development at Catalent Pharma Solutions and served in several senior global Quality, Operations and Business Unit leadership roles during her 8 year tenure. In addition, she has held progressive operational management roles at GE Healthcare and Amersham Health. Christine started her career as a Microbiologist, and holds a B.S. in Biology from Lenoir Rhyne College.
Eric Bishop, Vice President of Research and Development
Eric oversees the research and development team at Cygnus Technologies and is responsible for new product development and technical support. Eric joined Cygnus Technologies in 2010, bringing a background in R&D for several biopharmaceutical companies. He holds multiple degrees, including an MBA from Hood College, an M.S. in biotechnology from Johns Hopkins University and a B.S. from Radford University.
David Weber, Vice President and Chief Commercial Officer
David comes to Maravai LifeSciences with over 35 years of experience in life sciences industry commercial leadership and general management. David is responsible for all marketing, sales, product development, commercial strategy, service, and support for all Maravai LifeSciences portfolio companies. Prior to joining Maravai LifeSciences, David served as Executive Vice President and Chief Commercial Officer for Affymetrix leading up to its acquisition by Thermo Fisher Scientific. Earlier in his career, David held a variety of commercial leadership roles in life science companies including Amersham Biosesciences (GE Healthcare), Eksigent Technologies, Cyntellect, Stratagene, and The Linus Group.
Harjit Kullar, Vice President of Marketing
Harjit comes to Maravai LifeSciences with over 15 years of experience in sales and marketing in the life sciences and diagnostics industries, most recently holding the position of Vice President of Marketing at Transgenomic. Earlier in his career, Harjit held a variety of commercial leadership roles in life science companies including Bio-Rad Laboratories, Thermo Fisher Scientific, Life Technologies, LifeSpan Biosesciences and Abcam. Harjit received a BSc in Biochemistry & Pharmacology from University of Southampton, a Ph.D. in Cancer Biology from University of Birmingham and an MBA from University of Cambridge.